Search for a trial

Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients

The main objective of this study is to depict microglial activation behind a closed BBB in vivo and possibly establish an imaging marker of fast clinical progression, we will aim at visualizing microglial activity in vivo in cortical and hippocampal…

An Open label Follow-On Study to Assess the Ongoing Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis.

To obtain ongoing safety data of 500 mg MBP8298 given intravenously every six months in subjects previously enrolled in the MBP8298-01 study *A Double Blind Placebo Controlled Multi-Centre Study to Evaluate the Efficacy and Safety of MBP8298 in…

Influence on brain perfusion and metabolism through pharmacologic agents

In this study we would like to investigate whether cerebral perfusie and cerebral metabolism can be influenced with pharmacological agents in patients with MS and in healthy control persons. Cerebral perfusion and cerebral metabolism wil be measured…

A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction and function in patients with multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)

Primary objective: - to evaluate the effects of fampridine on eye movements in MS patients with a unilateral or bilateral INO. Secondary objectives:- to determine whether there is an association between MRI signal of the medial longitudinal…

Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This study has been transitioned to CTIS with ID 2023-507885-21-00 check the CTIS register for the current data. Primary objective:- To assess the long-term safety and tolerability of efgartigimod PH20 SC (efgartigimod co formulated with recombinant…

A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of PBKR03 Administered to Pediatric Subjects with Early Infantile Krabbe Disease (Globoid Cell Leukodystrophy) (GALax-C)

This first-in-human study is planned to include both a dose ranging phase and a confirmatory phase, with the intention that all data collected throughout the study may support registration. The dose ranging phase will be conducted in cohorts of 3-4…

A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 (previously BIVV020) in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)

This study has been transitioned to CTIS with ID 2024-512345-16-00 check the CTIS register for the current data. The purpose of this BIVV020 Phase 2 study is to determine the preliminary efficacy, safety, and tolerability of BIVV020 in three CIDP…

[11C]MeDAS PET: an imaging tool for quantitative assessment of changes in myelin density over time in multiple sclerosis

The objective of this study is to evaluate [11C]MeDAS PET as a quantitative method for assessment of changes in myelin density over time and thus the efficacy of [11C]MeDAS PET to image myelin degradation and repair.

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP04 is a Phase 2A, multicenter, single-arm, open-label study with the primary objective of evaluating the long-term safety and tolerability of rozanolixizumab when administered as weekly subcutaneous (sc) infusion in subjects with CIDP. The…

Efficacy of add-on high-dose simvastatin on markers for disease progression in MS patients treated with ocrelizumab and natalizumab (SIMSON), a phase II clinical trial.

To assess the efficacy of add-on high-dose simvastatin on markers for disease progression in MS patients treated with natalizumab or ocrelizumab for at least six months.

Neuroprotective Effects of Exercise in People with Progressive Multiple Sclerosis: a phase II trial

The primary aim of this phase II trial is to assess whether a progressive resistance training program can slow down neurodegeneration in people with PMS. Additional objectives of this study are: 1. To determine the effect of exercise on disability.…